Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business
Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.
Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.